<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> (APS) is diagnosed in the presence of vascular <z:mp ids='MP_0005048'>thrombosis</z:mp> or pregnancy morbidity occurring in patients with circulating <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (<z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> [LA] and/or IgG/IgM anticardiolipin [aCL] and/or IgG/IgM anti-beta2glycoprotein I [abeta2GPI] antibodies) </plain></SENT>
<SENT sid="1" pm="."><plain>Each test may identify different autoantibodies; a single test makes the diagnosis possible when positive on two or more occasions at least 12 weeks apart </plain></SENT>
<SENT sid="2" pm="."><plain>However, single test positivity may be unrelated to pathogenic antibodies, which are now considered to be a subclass of abeta2GPI antibodies directed against the domain I of this protein </plain></SENT>
<SENT sid="3" pm="."><plain>Conversely, <z:hpo ids='HP_0000001'>all</z:hpo> three positive tests identify a single class of abeta2GPI antibodies, thus identifying high-risk patients with APS </plain></SENT>
</text></document>